Journal of Medical Case Reports, 2011 Introduction Gastrointestinal stromal tumors are a rare neoplasm exhibiting, in most cases, mutations of c-kit. Imatinib mesylate is the standard treatment for patients who have advanced gastrointestinal stromal tumors.
Maazaz Khalid +11 more
doaj +1 more source
A rare case of melanosis of the hard palate mucosa in a patient with chronic myeloid leukemia [PDF]
, 2015 Imatinib Mesylate, also known as Gleevec or ST1-571, is a tyrosine-kinase inhibitor used as the gold standard medication for the chronic myeloid leukemia (CML); Imatinib has indeed deeply revolutionized the CML therapy allowing most patients to have a ...
Bosco, Daniela +4 more
core +3 more sources
Postoperative Cure for Metastatic Gastrointestinal Stromal Tumor
The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2018 Gastrointestinal stromal tumor (GIST) is a mesenchymal tumor derived from Cajal cells originating from the myotonic plexus. The expression of tyrosine kinase (KIT) membrane receptors that are active on KIT is inhibited by the KIT inhibitor imatinib ...
Eun Hyea Park +3 more
doaj +1 more source
Clinical implications of discordant early molecular responses in CML patients treated with imatinib [PDF]
, 2019 A reduction in BCR-ABL1/ABL1IS transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients.
Accurso V. +23 more
core +1 more source
A dual origin for Bcr-Abl gene translocation/fusion as dynamics of synergism of the hematopoietic stem cell and hemangioblast in chronic myeloid leukemia [PDF]
, 2015 Contextual BCR-ABL tyrosine kinase over-activity determines in formulated fashion the emergence of proliferation and anti-apoptosis that arise largely as derived phenomena of otherwise homeostatic mechanisms of the c-ABL gene within hematopoietic ...
Agius, Lawrence M.
core +1 more source
Long-term follow-up of Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in children and adolescents managed at a single institution over a 20-year period [PDF]
, 2005 Chronic myeloid leukaemia (CML) is rare in childhood. In our Institution we managed 30 consecutive Ph+CML patients aged
DE CUIA MR +7 more
core +1 more source
Role of growth factors in the pathogenesis of tissue fibrosis in systemic sclerosis. [PDF]
, 2010 The most severe clinical and pathologic manifestations of systemic sclerosis (SSc) are the result of a fibrotic process characterized by the excessive and often progressive deposition of collagen and other connective tissue macromolecules in skin and ...
Castro, Susan V. +2 more
core +2 more sources
BMC Cancer, 2010 Background About 80% of patients with GIST would experience tumor recurrence or metastasis after radical resection. The most common site of the metastasis is the liver. Imatinib mesylate has been proved effective for advanced GIST.
Jiang Ming +4 more
doaj +1 more source
Renal phosphate loss in Iraqi chronic myeloid leukemia patients treated by imatinib mesylate
Iraqi Journal of Hematology, 2020 BACKGROUND: The use of BCR-ABL tyrosine kinase inhibitor imatinib mesylate improved outcomes for patients with chronic myeloid leukemia (CML). Hypophosphatemia is found to be associated with imatinib mesylate use; the exact mechanism of this is not clear
Huda A Al-Taee, Azhar K Athab, Ala Ali
doaj +1 more source
Molecular Therapy: Oncolytics, 2021 Resistance to the BCR-ABL inhibitor imatinib mesylate poses a major problem for the treatment of chronic myeloid leukemia. Imatinib resistance often results from a secondary mutation in BCR-ABL that interferes with drug binding.
Yanjun Liu +8 more
doaj +1 more source